^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr del(17p)

    Related tests:
    17d
    CAR BCMA-70 CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Affiliated Hospital to Academy of Military Medical Sciences
    New P1 trial
    |
    TP53 (Tumor protein P53) • CD70 (CD70 Molecule)
    |
    TP53 mutation • Chr del(17p)
    |
    cyclophosphamide • fludarabine IV
    21d
    Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2028 | Initiation date: Jan 2026 --> Apr 2026 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Chr del(17p)
    |
    clonoSEQ
    |
    carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • dexamethasone injection
    1m
    Imaging Flow Cytometry Detection of Cytogenetic Abnormalities in Circulating CD34+ Cells Predicts Leukemic Transformation in Myelofibrosis. (PubMed, Cytometry A)
    This pilot study demonstrates that imaging flow cytometry-based FISH of circulating CD34/CD45-positive cells enables real-time, blood-based surveillance for cytogenetic evolution in myelofibrosis. The ability to dynamically track clone size and hierarchy highlights its potential as an early predictor of leukemic transformation in myelofibrosis.
    Journal
    |
    CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    Chr del(17p) • Chr del(5q)
    1m
    Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial (clinicaltrials.gov)
    P1/2, N=27, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • PAX5 (Paired Box 5) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • SOX11 (SRY-Box Transcription Factor 11) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A deletion
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    2ms
    Efficacy of melflufen in multiple myeloma with mutated or deleted TP53. (PubMed, Exp Hematol Oncol)
    Post-hoc analysis of the OCEAN trial melflufen-treated del(17p) patient population also demonstrated favorable progression free survival compared to pomalidomide-treated cohort. Our insights into the molecular mechanisms of melflufen activity in TP53-/- myeloma support its clinical efficacy and application in the del(17p) and TP53-/- patient population.Trial registration NCT03151811, registration 2017-05-09.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion
    |
    pomalidomide • Melflufen (melphalan flufenamide)
    3ms
    P17-132: Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting (clinicaltrials.gov)
    P=N/A, N=500, Recruiting, AbbVie | Active, not recruiting --> Recruiting | N=350 --> 500 | Trial completion date: Dec 2025 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2030
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • Chr del(17p) • TP53 mutation + Chr del(17p)
    |
    Venclexta (venetoclax)
    3ms
    ASSURE: Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (clinicaltrials.gov)
    P3, N=552, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr del(17p) • Chr del(11q) • IGH mutation
    |
    Calquence (acalabrutinib)
    4ms
    Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiation. (PubMed, Sci Transl Med)
    Together, our work identified genetic events linked to the initiation and malignant transformation of MM along the B cell lineage. These findings form the foundation for identifying potential therapeutic strategies for patients with RRMM by targeting MICs and their driving oncogenes.
    Journal
    |
    CD24 (CD24 Molecule) • IRF4 (Interferon regulatory factor 4) • SPI1 (Spi-1 Proto-Oncogene)
    |
    Chr del(17p)
    4ms
    Extrachromosomal circular DNA of multiple myeloma. (PubMed, J Cancer)
    We performed a Circle-seq analysis of MM and investigated the heterogeneity of EccDNA. Analysis of data from clinical studies and basic experiments revealed that the gene carried on EccDNA most likely contributed to the increased tolerance of bortezomib in MM with del(17p).
    Journal
    |
    ANXA5 (Annexin A5)
    |
    Chr del(17p)
    |
    bortezomib
    5ms
    Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients. (PubMed, Clin Lymphoma Myeloma Leuk)
    in real world, more than one third of MM patients do not have baseline FISH data. Nevertheless, cytogenetics and ECOG PS can be used for prognostic staging and for tailoring therapy.
    Journal • Real-world evidence • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    Chr del(17p) • Chr t(11;14)
    6ms
    The Prognostic Value of Amplification of the MYCC and MYCN Oncogenes in Russian Patients with Medulloblastoma. (PubMed, Diseases)
    Amplification of the MYC gene is a predictor of poor overall survival to therapy and a high risk of metastatic relapse. This allows us to more accurately stratify patients into risk groups in order to determine the intensity and duration of therapy.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • RARA (Retinoic Acid Receptor Alpha)
    |
    Chr del(17p)
    7ms
    T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1)
    |
    TP53 mutation • Chr del(17p) • FLT3 mutation • RUNX1 mutation • ASXL1 mutation
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV